Business Insider

LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edema

SEATTLE, May 7, 2021 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular damage and diseases, today announced research ...
Yahoo Finance

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

SEATTLE, November 04, 2024--(BUSINESS WIRE)--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the U.S. Food & Drug ...
Healio

EUROLIGHT registry study to evaluate photobiomodulation in dry AMD

Please provide your email address to receive an email when new articles are posted on . LumiThera announced the EUROLIGHT registry study will evaluate the safety, efficacy and biomarkers of ...
Business Wire

LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients

SEATTLE--(BUSINESS WIRE)--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced an update on the regulatory status of the ...
Healio

LumiThera expands Valeda research into diabetic retinopathy

Please provide your email address to receive an email when new articles are posted on . LumiThera is expanding research of its photobiomodulation platform, the Valeda light delivery system, with new ...
Business Insider

LumiThera Announces an Agreement with Andrec Corporation S.A. to Distribute the Valeda Light Delivery System in Colombia and Several Latin American Countries

SEATTLE, March 7, 2019 /PRNewswire/ -- LumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and diseases, announced ...
Business Wire

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

SEATTLE--(BUSINESS WIRE)--LumiThera, Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular damage and disease, today announced a new Category III CPT code ...
Newswire

Valeda Light Delivery System Receives 2019 Medical Design Excellence Award

LumiThera, Inc. is a leader in the use of photobiomodulation for the treatment of acute and chronic ocular diseases and disorders. Age-related macular degeneration (AMD) is the leading cause of ...
Seeking Alpha

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

GENEVA--(BUSINESS WIRE)-- Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based ...
Finanznachrichten

LumiThera Inc.: LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda Light Delivery ...

LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the initiation of the largest PBM trial ever conducted in patients ...
News Medical

Study reveals how photobiomodulation improves cognitive alterations from chronic stress

Some neurological disorders can be improved through photobiomodulation, a non-invasive technique based on the application of low-intensity light to stimulate altered functions in specific regions of ...